FDA rejects ivonescimab in Summit’s EGFR-NSCLC application
FDA rejected Summit’s ivonescimab after HARMONi cut progression or death risk by 48% but failed to show a statistically significant overall-survival benefit.
TAG P-9899 · 653 words on the filing

Summary of findings
- FDA issued a CRL on Sunday for ivonescimab in previously treated EGFR-mutated NSCLC.
- HARMONi reduced the risk of progression or death by 48%, but its OS endpoint missed statistical significance.
- AstraZeneca invested $2bn for a 10% Summit stake in September and formed an ADC-combination collaboration.
- HARMONi-3 could report initial squamous NSCLC OS and PFS data by year-end; non-squamous results are expected in the first half of 2027.
- Summit’s 2022 Akeso licensing agreement is valued at up to $5bn and covers the US, Canada, Europe and Japan.
Olivia Hart
The US Food and Drug Administration (FDA) issued a complete response letter (CRL) on Sunday, rejecting Summit Therapeutics’ investigational ivonescimab for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). The CRL concerned the investigational therapy’s biologics licence application (BLA).
The FDA concluded that the available clinical evidence did not establish a sufficiently favourable benefit-risk profile to support approval.
HARMONi PFS result did not settle the OS endpoint
The Phase III HARMONi trial evaluated ivonescimab plus chemotherapy against chemotherapy alone in patients whose EGFR-mutated NSCLC had progressed after prior tyrosine kinase inhibitor (TKI) treatment. Ivonescimab produced a statistically significant progression-free survival (PFS) improvement, reducing the risk of disease progression or death by 48% versus chemotherapy alone.
The overall survival (OS) endpoint did not reach statistical significance. Summit subsequently submitted updated survival data to the FDA and said the new data indicated consistent improvement across Asian and Western patient subgroups. The regulator maintained that PFS benefit, without a statistically significant OS improvement, could not establish a positive benefit-risk profile.
What does the rejection change for Summit’s pipeline?
For a team tracking launch timing, the immediate change is clear: the BLA has not produced US approval in previously treated EGFR-mutated NSCLC. Summit said it was disappointed by the decision but remained committed to advancing ivonescimab’s clinical development across multiple cancer indications. The wider programme continues across several solid tumours and combination regimens.
That work now leans more heavily on a first-line trial with a different comparator and a broader commercial collaborator.
HARMONi-3 becomes the next major readout
Attention is shifting to the Phase III HARMONi-3 trial in first-line NSCLC. It evaluates ivonescimab plus chemotherapy against Merck’s pembrolizumab (Keytruda) plus chemotherapy. The study therefore tests ivonescimab against a pembrolizumab-based chemotherapy regimen.
Timing is split by histology:
- Initial overall survival and progression-free survival results for patients with squamous NSCLC could arrive by the end of this year.
- Results from the non-squamous NSCLC cohort are expected in the first half of 2027.
HARMONi-3 now carries greater weight because the post-TKI HARMONi package did not satisfy FDA’s approval standard.
AstraZeneca commits $2bn and an ADC collaboration
In September, AstraZeneca announced a $2bn investment in Summit, securing a 10% stake in the US biotech. The transaction also established a collaboration to investigate combinations of ivonescimab with AstraZeneca’s antibody-drug conjugate cancer therapies.
Interest in bispecific immunotherapies continues to grow, and the FDA rejection may create an opportunity for competing developers of PD-(L)1/VEGF bispecific antibodies to advance their clinical programmes. The named competitors are:
- BioNTech and Bristol Myers Squibb
- Pfizer and 3SBio
- AbbVie and RemeGen
Ivonescimab’s mechanism and rights split
Akeso developed ivonescimab as a bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). PD-1 inhibition aims to prevent cancer cells from evading immune detection, while VEGF blockade aims to disrupt the formation of blood vessels that supply tumours with oxygen and nutrients.
The dual-targeting design combines immune-checkpoint inhibition with anti-angiogenic activity. Summit acquired commercial rights in the US, Canada, Europe and Japan from Akeso in 2022, under a licensing agreement valued at up to $5bn. Akeso retained rights in China and other markets, where ivonescimab has secured approvals for three NSCLC indications.
The drug drew considerable industry interest after positive clinical findings in China. Those findings included a head-to-head study in which ivonescimab outperformed Merck’s Keytruda on PFS among patients with PD-L1-positive NSCLC.
For Summit’s US regulatory team, the immediate change is narrow but material: FDA has rejected the application supported by HARMONi. The 48% PFS result is established; the unresolved issue is statistically significant OS evidence. HARMONi-3 now carries greater weight, although it addresses first-line NSCLC and a pembrolizumab-based comparator.
via FDA industry wire (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- C-4460
- K-1065
- C-6506
- V-1848
- C-7994